Prostate Cancer最新文献_第7页

Evolving Paradigm of Radiotherapy for High-Risk Prostate Cancer: Current Consensus and Continuing Controversies. 高危前列腺癌放射治疗范式的演变：当前共识与持续争议。

IF 4.2

Prostate Cancer Pub Date : 2016-01-01 Epub Date: 2016-05-23 DOI: 10.1155/2016/2420786

Aditya Juloori, Chirag Shah, Kevin Stephans, Andrew Vassil, Rahul Tendulkar

引用次数: 0

Predicting Low-Risk Prostate Cancer from Transperineal Saturation Biopsies. 经会阴饱和活检预测低风险前列腺癌。

IF 4.2

Prostate Cancer Pub Date : 2016-01-01 Epub Date: 2016-04-11 DOI: 10.1155/2016/7105678

Pim J van Leeuwen, Amila Siriwardana, Monique Roobol, Francis Ting, Daan Nieboer, James Thompson, Warick Delprado, Anne-Marie Haynes, Phillip Brenner, Phillip Stricker

{"title":"Predicting Low-Risk Prostate Cancer from Transperineal Saturation Biopsies.","authors":"Pim J van Leeuwen, Amila Siriwardana, Monique Roobol, Francis Ting, Daan Nieboer, James Thompson, Warick Delprado, Anne-Marie Haynes, Phillip Brenner, Phillip Stricker","doi":"10.1155/2016/7105678","DOIUrl":"https://doi.org/10.1155/2016/7105678","url":null,"abstract":"Introduction. To assess the performance of five previously described clinicopathological definitions of low-risk prostate cancer (PC). Materials and Methods. Men who underwent radical prostatectomy (RP) for clinical stage ≤T2, PSA <10 ng/mL, Gleason score <8 PC, diagnosed by transperineal template-guided saturation biopsy were included. The performance of five previously described criteria (i.e., criteria 1-5, criterion 1 stringent (Gleason score 6 + ≤5 mm total max core length PC + ≤3 mm max per core length PC) up to criterion 5 less stringent (Gleason score 6-7 with ≤5% Gleason grade 4) was analysed to assess ability of each to predict insignificant disease in RP specimens (defined as Gleason score ≤6 and total tumour volume <2.5 mL, or Gleason score 7 with ≤5% grade 4 and total tumour volume <0.7 mL). Results. 994 men who underwent RP were included. Criterion 4 (Gleason score 6) performed best with area under the curve of receiver operating characteristics 0.792. At decision curve analysis, criterion 4 was deemed clinically the best performing transperineal saturation biopsy-based definition for low-risk PC. Conclusions. Gleason score 6 disease demonstrated a superior trade-off between sensitivity and specificity for clarifying low-risk PC that can guide treatment and be used as reference test in diagnostic studies. ","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2016 ","pages":"7105678"},"PeriodicalIF":4.2,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2016/7105678","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34458293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prostate cancer patients' refusal of cancer-directed surgery: a statewide analysis. 前列腺癌患者拒绝癌症定向手术:一项全州范围的分析。

IF 4.2

Prostate Cancer Pub Date : 2015-01-01 Epub Date: 2015-04-20 DOI: 10.1155/2015/829439

K M Islam, Jiajun Wen

{"title":"Prostate cancer patients' refusal of cancer-directed surgery: a statewide analysis.","authors":"K M Islam, Jiajun Wen","doi":"10.1155/2015/829439","DOIUrl":"https://doi.org/10.1155/2015/829439","url":null,"abstract":"Introduction. Prostate cancer is the most common cancer among men in USA. The surgical outcomes of prostate cancer remain inconsistent. Barriers such as socioeconomic factors may play a role in patients' decision of refusing recommended cancer-directed surgery. Methods. The Nebraska Cancer Registry data was used to calculate the proportion of prostate cancer patients recommended the cancer-directed surgery and the surgery refusal rate. Multivariate logistic regression was applied to analyze the socioeconomic indicators that were related to the refusal of surgery. Results. From 1995 to 2012, 14,876 prostate cancer patients were recommended to undergo the cancer-directed surgery in Nebraska, and 576 of them refused the surgery. The overall refusal rate of surgery was 3.9% over the 18 years. Patients with early-stage prostate cancer were more likely to refuse the surgery. Patients who were Black, single, or covered by Medicaid/Medicare had increased odds of refusing the surgery. Conclusion. Socioeconomic factors were related to the refusal of recommended surgical treatment for prostate cancer. Such barriers should be addressed to improve the utilization of surgical treatment and patients' well-being. ","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2015 ","pages":"829439"},"PeriodicalIF":4.2,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2015/829439","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33303414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 12

Analysis of Prostate Cancer Susceptibility Variants in South African Men: Replicating Associations on Chromosomes 8q24 and 10q11. 南非男性前列腺癌易感性变异分析:染色体8q24和10q11上的复制关联

IF 4.2

Prostate Cancer Pub Date : 2015-01-01 Epub Date: 2015-08-12 DOI: 10.1155/2015/465184

Pedro Fernandez, Muneeb Salie, Danielle du Toit, Andre van der Merwe

{"title":"Analysis of Prostate Cancer Susceptibility Variants in South African Men: Replicating Associations on Chromosomes 8q24 and 10q11.","authors":"Pedro Fernandez, Muneeb Salie, Danielle du Toit, Andre van der Merwe","doi":"10.1155/2015/465184","DOIUrl":"https://doi.org/10.1155/2015/465184","url":null,"abstract":"Genome-wide association studies (GWAS) have implicated single nucleotide polymorphisms (SNPs) on chromosomes 2p15, 6q25, 7p15.2, 7q21, 8q24, 10q11, 10q26, 11q13, 17q12, 17q24, 19q13, and Xp11, with prostate cancer (PCa) susceptibility and/or tumour aggressiveness, in populations of African, European, and Asian ancestry. The objective of this study was to confirm these associations in South African Mixed Ancestry and White men. We evaluated 17 prioritised GWAS SNPs in South African cases (331 Mixed Ancestry and 155 White) and controls (178 Mixed Ancestry and 145 White). The replicated SNP associations for the different South African ethnic groups were rs7008482 (8q24) (p = 2.45 × 10(-5)), rs6983267 (8q24) (p = 4.48 × 10(-7)), and rs10993994 (10q11) (p = 1.40 × 10(-3)) in Mixed Ancestry men and rs10993994 (p = 1.56 × 10(-9)) in White men. No significant associations were observed for the analyses stratified by disease aggressiveness in the individual and the combined population group analysis. The present study demonstrates that a number of known PCa susceptibility variants may contribute to disease susceptibility in South African men. Larger genetic investigations extended to other South African population groups are warranted to confirm the role of these and other SNPs in disease susceptibility. ","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2015 ","pages":"465184"},"PeriodicalIF":4.2,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2015/465184","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34052253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 18

Thioredoxin 1 in Prostate Tissue Is Associated with Gleason Score, Erythrocyte Antioxidant Enzyme Activity, and Dietary Antioxidants. 前列腺组织中的硫氧还蛋白1与Gleason评分、红细胞抗氧化酶活性和膳食抗氧化剂相关

IF 4.2

Prostate Cancer Pub Date : 2015-01-01 Epub Date: 2015-08-18 DOI: 10.1155/2015/728046

Terrence M Vance, Gissou Azabdaftari, Elena A Pop, Sang Gil Lee, L Joseph Su, Elizabeth T H Fontham, Jeannette T Bensen, Susan E Steck, Lenore Arab, James L Mohler, Ming-Hui Chen, Sung I Koo, Ock K Chun

{"title":"Thioredoxin 1 in Prostate Tissue Is Associated with Gleason Score, Erythrocyte Antioxidant Enzyme Activity, and Dietary Antioxidants.","authors":"Terrence M Vance, Gissou Azabdaftari, Elena A Pop, Sang Gil Lee, L Joseph Su, Elizabeth T H Fontham, Jeannette T Bensen, Susan E Steck, Lenore Arab, James L Mohler, Ming-Hui Chen, Sung I Koo, Ock K Chun","doi":"10.1155/2015/728046","DOIUrl":"https://doi.org/10.1155/2015/728046","url":null,"abstract":"Background. Prostate cancer is the most common noncutaneous cancer and second leading cause of cancer-related mortality in men in the US. Growing evidence suggests that oxidative stress is involved in prostate cancer. Methods. In this study, thioredoxin 1 (Trx 1), an enzyme and subcellular indicator of redox status, was measured in prostate biopsy tissue from 55 men from the North Carolina-Louisiana Prostate Cancer Project. A pathologist blindly scored levels of Trx 1. The association between Trx 1 and the Gleason score, erythrocyte antioxidant enzyme activity, and dietary antioxidant intake was determined using Fisher's exact test. Results. Trx 1 levels in benign prostate tissue in men with incident prostate cancer were positively associated with the Gleason score (P = 0.01) and inversely associated with dietary antioxidant intake (P = 0.03). In prostate cancer tissue, Trx 1 levels were associated with erythrocyte glutathione peroxidase activity (P = 0.01). No association was found for other erythrocyte enzymes. Greater Gleason score of malignant tissue corresponds to a greater difference in Trx 1 levels between malignant and benign tissue (P = 0.04). Conclusion. These results suggest that the redox status of prostate tissue is associated with prostate cancer grade and both endogenous and exogenous antioxidants. ","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2015 ","pages":"728046"},"PeriodicalIF":4.2,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2015/728046","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34060588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 9

Triptorelin in the Relief of Lower Urinary Tract Symptoms in Advanced Prostate Cancer Patients: The RESULT Study. 雷普妥林缓解晚期前列腺癌患者下尿路症状的结果研究

IF 4.2

Prostate Cancer Pub Date : 2015-01-01 Epub Date: 2015-01-28 DOI: 10.1155/2015/978194

Alexandre Peltier, Fouad Aoun, Vincent De Ruyter, Patrick Cabri, Roland Van Velthoven

{"title":"Triptorelin in the Relief of Lower Urinary Tract Symptoms in Advanced Prostate Cancer Patients: The RESULT Study.","authors":"Alexandre Peltier, Fouad Aoun, Vincent De Ruyter, Patrick Cabri, Roland Van Velthoven","doi":"10.1155/2015/978194","DOIUrl":"https://doi.org/10.1155/2015/978194","url":null,"abstract":"This prospective, noninterventional, open-label, multicentre, Belgian study assessed the prevalence of moderate to severe lower urinary tract symptoms (LUTS) in patients with locally advanced or metastatic prostate cancer scheduled to receive triptorelin therapy and its effects on LUTS were evaluated focusing on symptom relief and changes in quality of life (QOL) related to urinary symptoms (November 2006 to May 2010). Inclusion criteria were age >18 years, histologically confirmed advanced or metastatic prostate cancer, and life expectancy ≥12 months. Exclusion criteria were treatment with any LHRH analogue within the last 6 months or any other investigational agent within the last 3 months before study entry. Patients who received one or more triptorelin doses and had one or more efficacy assessments were evaluated. In total, 325 patients were included with a median age of 74 years (50 to 95 years). Mean age at first diagnosis was 73 ± 8 years. Moderate (IPSS 8-19) to severe (IPSS ≥ 20) LUTS were observed in 62% of patients. Triptorelin reduced LUTS severity. This improvement was perceived within the first 24 weeks of treatment and was maintained after 48 weeks. A decrease in PSA level was also observed. ","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2015 ","pages":"978194"},"PeriodicalIF":4.2,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2015/978194","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33065032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 11

Current Patterns of Management of Advanced Prostate Cancer in Routine Clinical Practice in Spain. 西班牙晚期前列腺癌常规临床实践的当前管理模式。

IF 4.2

Prostate Cancer Pub Date : 2015-01-01 Epub Date: 2015-07-13 DOI: 10.1155/2015/186740

Maria José Ribal, Juan Ignacio Martínez-Salamanca, Camilo García Freire

{"title":"Current Patterns of Management of Advanced Prostate Cancer in Routine Clinical Practice in Spain.","authors":"Maria José Ribal, Juan Ignacio Martínez-Salamanca, Camilo García Freire","doi":"10.1155/2015/186740","DOIUrl":"https://doi.org/10.1155/2015/186740","url":null,"abstract":"Objective. To describe urologists' practice patterns when managing patients with advanced prostate cancer (PCa) in Spain. Methods. This was an observational study conducted by 120 urologists using retrospective data of advanced PCa patients attending hospitals and outpatient centers. Results. Urologists evaluated a total of 375 patients (mean age: 75 years; ECOG 0-1: 77%; mean serum PSA levels at study entry: 50.5 ng/Ml). Approximately 50% of patients had bone metastases, and 60.6% experienced pain as the main symptom of progressive disease. Primary androgen deprivation therapy (ADT) use was 99.7%, with continuous ADT as the dominant strategy (91.9%). After failure of initial ADT, antiandrogen withdrawal was the next method most commonly used in 57% of patients. Choice of secondary hormonal treatment was made mostly by urologists (96%), who continued to monitor patients. Patient follow-up after chemotherapy and supportive care were mainly done in urology units, although responsibility was shared with medical oncologists and radiologists. Conclusion. The urologists' attitudes towards management of PCa in the routine practice in Spain show the urologist as an integral component even when patients progress to advanced stages of the disease. ","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2015 ","pages":"186740"},"PeriodicalIF":4.2,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2015/186740","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33899944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5

Cellular Plasticity in Prostate Cancer Bone Metastasis. 前列腺癌骨转移中的细胞可塑性

IF 4.2

Prostate Cancer Pub Date : 2015-01-01 Epub Date: 2015-06-03 DOI: 10.1155/2015/651580

Dima Y Jadaan, Mutaz M Jadaan, John P McCabe

{"title":"Cellular Plasticity in Prostate Cancer Bone Metastasis.","authors":"Dima Y Jadaan, Mutaz M Jadaan, John P McCabe","doi":"10.1155/2015/651580","DOIUrl":"https://doi.org/10.1155/2015/651580","url":null,"abstract":"Purpose. Experimental data suggest that tumour cells can reversibly transition between epithelial and mesenchymal states (EMT and MET), a phenomenon known as cellular plasticity. The aim of this review was to appraise the clinical evidence for the role of cellular plasticity in prostate cancer (PC) bone metastasis. Methods. An electronic search was performed using PubMed for studies that have examined the differential expression of epithelial, mesenchymal, and stem cell markers in human PC bone metastasis tissues. Results. The review included nineteen studies. More than 60% of the studies used ≤20 bone metastasis samples, and there were several sources of heterogeneity between studies. Overall, most stem cell markers analysed, except for CXCR4, were positively expressed in bone metastasis tissues, while the expression of EMT and MET markers was heterogeneous between and within samples. Several EMT and stemness markers that are involved in osteomimicry, such as Notch, Met receptor, and Wnt/β pathway, were highly expressed in bone metastases. Conclusions. Clinical findings support the role of cellular plasticity in PC bone metastasis and suggest that epithelial and mesenchymal states cannot be taken in isolation when targeting PC bone metastasis. The paper also highlights several challenges in the clinical detection of cellular plasticity. ","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2015 ","pages":"651580"},"PeriodicalIF":4.2,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2015/651580","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33880429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 24

Atypical Small Acinar Proliferation: Repeat Biopsy and Detection of High Grade Prostate Cancer. 非典型小腺泡增生:重复活检和高级别前列腺癌的检测。

IF 4.2

Prostate Cancer Pub Date : 2015-01-01 Epub Date: 2015-09-14 DOI: 10.1155/2015/810159

Andrew Leone, Katherine Rotker, Christi Butler, Anthony Mega, Jianhong Li, Ali Amin, Stephen F Schiff, Gyan Pareek, Dragan Golijanin, Joseph F Renzulli

{"title":"Atypical Small Acinar Proliferation: Repeat Biopsy and Detection of High Grade Prostate Cancer.","authors":"Andrew Leone, Katherine Rotker, Christi Butler, Anthony Mega, Jianhong Li, Ali Amin, Stephen F Schiff, Gyan Pareek, Dragan Golijanin, Joseph F Renzulli","doi":"10.1155/2015/810159","DOIUrl":"https://doi.org/10.1155/2015/810159","url":null,"abstract":"Purpose. Atypical small acinar proliferation (ASAP) is diagnosed in 1-2% of prostate biopsies. 30-40% of patients with ASAP may be diagnosed with prostate cancer (PCa) on repeat biopsy. Our objective was to examine the association between ASAP and subsequent diagnosis of intermediate/high risk PCa. Materials and Methods. Ninety-six patients who underwent prostate biopsy from 2000 to 2013 and were diagnosed with ASAP were identified. Clinicopathologic features were analyzed. Comparison was made between those with subsequent PCa on repeat biopsy and those with benign repeat pathology. Results. 56/96 (58%) patients had a repeat biopsy. 22/56 (39%) were subsequently diagnosed with PCa. There was no significant difference in patients' characteristics. Presence of HGPIN on initial biopsy was associated with a benign repeat biopsy (68% versus 23%). 17/22 (77%) had Gleason grade (GG) 3+3 disease and only 5/22 (23%) had GG 3+4 disease. Conclusions. 22/56 patients (39%) of patients who underwent a subsequent prostate biopsy following a diagnosis of ASAP were found to have PCa. 77% of these men were diagnosed with GG 3+3 PCa. Only 23% were found to have intermediate risk PCa and no high risk PCa was identified. Immediate repeat prostate biopsy in patients diagnosed with ASAP may be safely delayed. A multi-institutional cohort is being analyzed. ","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2015 ","pages":"810159"},"PeriodicalIF":4.2,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2015/810159","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34140874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 14

Phase I Study of Anti-CD3 x Anti-Her2 Bispecific Antibody in Metastatic Castrate Resistant Prostate Cancer Patients. 抗 CD3 x 抗 Her2 双特异性抗体治疗转移性阉割耐药前列腺癌患者的 I 期研究。

IF 2.3

Prostate Cancer Pub Date : 2015-01-01 Epub Date: 2015-02-23 DOI: 10.1155/2015/285193

Ulka Vaishampayan, Archana Thakur, Ritesh Rathore, Nicola Kouttab, Lawrence G Lum

{"title":"Phase I Study of Anti-CD3 x Anti-Her2 Bispecific Antibody in Metastatic Castrate Resistant Prostate Cancer Patients.","authors":"Ulka Vaishampayan, Archana Thakur, Ritesh Rathore, Nicola Kouttab, Lawrence G Lum","doi":"10.1155/2015/285193","DOIUrl":"10.1155/2015/285193","url":null,"abstract":"Background. New nontoxic targeted approaches are needed for patients with castrate resistant prostate cancer (CRPC). Our preclinical studies show that activated T cells (ATC) armed with anti-CD3 x anti-Her2 bispecific antibody (Her2Bi) kill prostate cancer cells lines, induce a Th1 cytokine pattern upon engagement of tumor cells, prevent the development of prostate tumors, and retard tumor growth in immunodeficient mice. These studies provided strong rationale for our phase I dose-escalation pilot study to test ATC armed with Her2Bi (aATC) for safety in men with CRPC. Methods. Seven of 8 men with CRPC were evaluable after receiving two infusions per week for 4 weeks. The men received 2.5, 5 or 10 × 10(9) aATC per infusion with low dose interleukin-2 and granulocyte-macrophage colony stimulating factor. Results. There were no dose limiting toxicities, and there was 1 partial responder and 3 of 7 patients had significant decreases in their PSA levels and pain scores. Immune evaluations of peripheral blood mononuclear cells in 2 patients before and after immunotherapy showed increases in IFN-γ EliSpot responses and Th1 serum cytokines. Conclusions. These results provide a strong rationale for developing phase II trials to determine whether aATC are effective for treating CRPC. ","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2015 ","pages":"285193"},"PeriodicalIF":2.3,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4352947/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33155792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0